These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 33531470)

  • 21. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.
    Theurillat JP; Udeshi ND; Errington WJ; Svinkina T; Baca SC; Pop M; Wild PJ; Blattner M; Groner AC; Rubin MA; Moch H; Prive GG; Carr SA; Garraway LA
    Science; 2014 Oct; 346(6205):85-89. PubMed ID: 25278611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.
    Blattner M; Liu D; Robinson BD; Huang D; Poliakov A; Gao D; Nataraj S; Deonarine LD; Augello MA; Sailer V; Ponnala L; Ittmann M; Chinnaiyan AM; Sboner A; Chen Y; Rubin MA; Barbieri CE
    Cancer Cell; 2017 Mar; 31(3):436-451. PubMed ID: 28292441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
    Zhang P; Wang D; Zhao Y; Ren S; Gao K; Ye Z; Wang S; Pan CW; Zhu Y; Yan Y; Yang Y; Wu D; He Y; Zhang J; Lu D; Liu X; Yu L; Zhao S; Li Y; Lin D; Wang Y; Wang L; Chen Y; Sun Y; Wang C; Huang H
    Nat Med; 2017 Sep; 23(9):1055-1062. PubMed ID: 28805822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.
    Geng C; Rajapakshe K; Shah SS; Shou J; Eedunuri VK; Foley C; Fiskus W; Rajendran M; Chew SA; Zimmermann M; Bond R; He B; Coarfa C; Mitsiades N
    Cancer Res; 2014 Oct; 74(19):5631-43. PubMed ID: 25274033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion.
    Blee AM; Liu S; Wang L; Huang H
    Oncotarget; 2016 Jun; 7(25):38319-38332. PubMed ID: 27223260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression.
    Gan W; Dai X; Lunardi A; Li Z; Inuzuka H; Liu P; Varmeh S; Zhang J; Cheng L; Sun Y; Asara JM; Beck AH; Huang J; Pandolfi PP; Wei W
    Mol Cell; 2015 Sep; 59(6):917-30. PubMed ID: 26344095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.
    Groner AC; Cato L; de Tribolet-Hardy J; Bernasocchi T; Janouskova H; Melchers D; Houtman R; Cato ACB; Tschopp P; Gu L; Corsinotti A; Zhong Q; Fankhauser C; Fritz C; Poyet C; Wagner U; Guo T; Aebersold R; Garraway LA; Wild PJ; Theurillat JP; Brown M
    Cancer Cell; 2016 Jun; 29(6):846-858. PubMed ID: 27238081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression.
    Fong KW; Zhao JC; Song B; Zheng B; Yu J
    Nat Commun; 2018 Nov; 9(1):5007. PubMed ID: 30479348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The emerging role of speckle-type POZ protein (SPOP) in cancer development.
    Mani RS
    Drug Discov Today; 2014 Sep; 19(9):1498-502. PubMed ID: 25058385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SPOP mutations in prostate cancer across demographically diverse patient cohorts.
    Blattner M; Lee DJ; O'Reilly C; Park K; MacDonald TY; Khani F; Turner KR; Chiu YL; Wild PJ; Dolgalev I; Heguy A; Sboner A; Ramazangolu S; Hieronymus H; Sawyers C; Tewari AK; Moch H; Yoon GS; Known YC; Andrén O; Fall K; Demichelis F; Mosquera JM; Robinson BD; Barbieri CE; Rubin MA
    Neoplasia; 2014 Jan; 16(1):14-20. PubMed ID: 24563616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.
    Bose R; Karthaus WR; Armenia J; Abida W; Iaquinta PJ; Zhang Z; Wongvipat J; Wasmuth EV; Shah N; Sullivan PS; Doran MG; Wang P; Patruno A; Zhao Y; ; Zheng D; Schultz N; Sawyers CL
    Nature; 2017 Jun; 546(7660):671-675. PubMed ID: 28614298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.
    Wang H; Barbieri CE; He J; Gao Y; Shi T; Wu C; Schepmoes AA; Fillmore TL; Chae SS; Huang D; Mosquera JM; Qian WJ; Smith RD; Srivastava S; Kagan J; Camp DG; Rodland KD; Rubin MA; Liu T
    J Transl Med; 2017 Aug; 15(1):175. PubMed ID: 28810879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase.
    Zhu H; Ren S; Bitler BG; Aird KM; Tu Z; Skordalakes E; Zhu Y; Yan J; Sun Y; Zhang R
    Cell Rep; 2015 Nov; 13(6):1183-1193. PubMed ID: 26527005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity.
    Grbesa I; Augello MA; Liu D; McNally DR; Gaffney CD; Huang D; Lin K; Ivenitsky D; Goueli R; Robinson BD; Khani F; Deonarine LD; Blattner M; Elemento O; Davicioni E; Sboner A; Barbieri CE
    Cell Rep; 2021 Sep; 36(10):109625. PubMed ID: 34496233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SPOP suppresses prostate cancer through regulation of CYCLIN E1 stability.
    Ju LG; Zhu Y; Long QY; Li XJ; Lin X; Tang SB; Yin L; Xiao Y; Wang XH; Li L; Zhang L; Wu M
    Cell Death Differ; 2019 Jun; 26(6):1156-1168. PubMed ID: 30237511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
    Shi Q; Zhu Y; Ma J; Chang K; Ding D; Bai Y; Gao K; Zhang P; Mo R; Feng K; Zhao X; Zhang L; Sun H; Jiao D; Chen Y; Sun Y; Zhao SM; Huang H; Li Y; Ren S; Wang C
    Mol Cancer; 2019 Nov; 18(1):170. PubMed ID: 31771591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex.
    Watanabe R; Maekawa M; Hieda M; Taguchi T; Miura N; Kikugawa T; Saika T; Higashiyama S
    Mol Biol Cell; 2020 Mar; 31(6):478-490. PubMed ID: 31967940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.
    Zong Y; Xin L; Goldstein AS; Lawson DA; Teitell MA; Witte ON
    Proc Natl Acad Sci U S A; 2009 Jul; 106(30):12465-70. PubMed ID: 19592505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SPOP suppresses pancreatic cancer progression by promoting the degradation of NANOG.
    Tan P; Xu Y; Du Y; Wu L; Guo B; Huang S; Zhu J; Li B; Lin F; Yao L
    Cell Death Dis; 2019 Oct; 10(11):794. PubMed ID: 31624231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells.
    Zhang L; Peng S; Dai X; Gan W; Nie X; Wei W; Hu G; Guo J
    Cancer Lett; 2017 Apr; 390():11-20. PubMed ID: 28089830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.